Laurus Labs Limited (LAURUSLABS) Operating Income 2022–TTM

Name: Laurus Labs Limited (LAURUSLABS) operating income history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-03

Laurus Labs Limited annual operating income for fiscal TTM was ₹18.9 billion, an increase of 44.4% from ₹13.1 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

LAURUSLABS Annual Operating Income

Operating Income (annual)	TTM → 2026-09-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Income (EBIT)	₹18.9B	₹13.1B	₹6.3B	₹3.9B	₹12.9B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LAURUSLABS Quarterly Operating Income

Operating Income (quarterly)	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-06-30
Operating Income (EBIT)	₹6.2B	₹5.1B	₹3.9B	₹3.6B	₹2.7B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

4507 Operating Income — Shionogi & Co., Ltd.
TORNTPHARM Operating Income — Torrent Pharmaceuticals Limited
4523 Operating Income — Eisai Co., Ltd.
4151 Operating Income — Kyowa Kirin Co., Ltd.
ZYDUSLIFE Operating Income — Zydus Lifesciences Limited
DRREDDY Operating Income — Dr. Reddy's Laboratories Limited

More LAURUSLABS metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All LAURUSLABS financial statements → Interactive LAURUSLABS charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.